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Background and objectives: Joubert syndrome (JS) is a genetically heterogeneous ciliopathy 
associated with more than 30 genes. The characteristics of kidney disease and genotype-
phenotype correlations have not been evaluated in a large cohort at a single center.  
Design, setting, participants, and measurements: We evaluated 97 individuals with JS at the NIH 
Clinical Center including abdominal ultrasonography, blood and urine chemistries, and DNA 
sequencing.  
Results:  Patients were ages 0.6 to 36 years (mean 9.0 + 7.6); 41 were female. Mutations were 
identified in 19 genes in 92 patients; two-thirds of the mutations resided in 6 genes: TMEM67, 
C5orf42, CC2D2A, CEP290, AHI1, and KIAA0586. Kidney disease was detected in 30%, most 
commonly in association with the following genes: CEP290 (6/6), TMEM67 (11/22), and AHI1 
(3/6). No kidney disease was identified in patients with mutations in C5orf42 (0/15) or 
KIAA0586 (0/6). Prenatal ultrasonography of kidneys was normal in 72% of patients with kidney 
disease. Specific types of kidney disease included nephronophthisis (31%), an overlap phenotype 
of autosomal recessive polycystic kidney disease (ARPKD)/nephronophthisis (35%), unilateral 
multicystic dysplastic kidney (10%), and indeterminate type cystic kidney disease (24%). Early-
onset hypertension occurred in 24% of patients with kidney disease.  Age at end-stage kidney 
disease (n=13) ranged from 6 to 24 years (mean, 11.3 + 4.8).  
Conclusions: Kidney disease occurs in up to one-third of JS patients, most commonly in those 
with mutations in CEP290, TMEM67 and AHI1. Patients with mutations in C5orf42 or 
KIAA0586 are less likely to develop kidney disease. Prenatal ultrasonography is a poor predictor 
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of kidney involvement in JS. Unilateral multicystic dysplastic kidney and ARPKD-like enlarged 
kidneys with early-onset hypertension can be part of the JS kidney phenotype.  
 
Introduction 
Fibrocystic kidney disease is a common feature in many ciliopathies including Meckel, Bardet-
Biedl and Joubert syndromes (JS)(1, 2).  First described in 1969(3), JS (OMIM 213300) is 
defined based on a characteristic set of cerebellum and midbrain abnormalities that collectively 
result in the diagnostic “molar tooth sign” on axial brain images(4) (Figure 1). The incidence of 
JS is estimated to range between 1:80,000 and 1:100,000(5). Core clinical features of JS 
observed shortly after birth include hypotonia and episodic tachypnea and/or apnea, followed 
later by developmental delay, ocular motor apraxia, truncal ataxia and speech apraxia(5, 6). Most 
patients have extra-neurological involvement that can include polydactyly, chorioretinal 
colobomas, retinal degeneration, congenital hepatic fibrosis, and/or fibrocystic kidney disease(5, 
7). This clinical heterogeneity led to the use of the term Joubert syndrome and related disorders 
which includes Senior-Løken (nephronophthisis and retinal degeneration) and COACH 
(colobomas, "oligophrenia" for cognitive impairment, ataxia, cerebellar vermis hypoplasia, 
and hepatic fibrosis) syndromes(8). For simplicity, the term JS refers to all patients with the 
“molar tooth sign” including patients with or without non-neurological disease(6). In this article, 
we use JS to include Senior-Løken and COACH syndromes.  
Like other syndromic ciliopathies, JS is characterized by extreme genetic heterogeneity, with 
more than 30 causative genes(5). The frequency of kidney disease in individual gene-specific 
subtypes of JS remains unknown; estimates range from 25% to 27%(9, 10). Most publications on 
5 
 
kidney involvement in the disease have been limited to small case series or retrospective 
multicenter reports based on questionnaires and medical records review(7, 9, 11-13). In1992, 
Saraiva and Baraitser(9) claimed kidney disease and retinal disease in JS were closely linked and 
only patients with retinal dystrophy were at risk for fibrocystic kidney disease. However,  many 
individuals with JS and kidney disease but no retinal degeneration have since been reported(5, 
7).  While the nephronophthisis in Senior-Løken syndrome(14) and cystic dysplastic kidneys in 
Arima syndrome(7) are relatively well described, the kidney disease in other JS patients is often 
reported in non-specific terms, noting only absence or presence of  “kidney cysts” and neglecting 
data on features such as blood pressure, kidney function, and delineation of the exact type of the 
fibrocytic kidney disease. Although many of the over 30 causative JS genes, including CEP290, 
NPHP1, AHI1, OFD1, RPGRIP1L, CC2D2A, TMEM67, TMEM216, TMEM138, and TMEM237, 
have been associated with kidney disease, correlations between genotype and kidney disease 
remain largely unknown(5, 15, 16).  
Here we describe the characteristics of kidney disease in 97 JS patients prospectively evaluated 
at a single center. We detail kidney ultrasonography (US), magnetic resonance imaging (MRI) of 
the kidneys, and kidney function tests in the context of the molecular genetic diagnosis, as well 
as other organ involvement including liver disease and ophthalmological features.   
Materials and Methods 
Patients 
All patients were prospectively evaluated at the National Institutes of Health (NIH) Clinical 
Center, between 2003 and 2014, under the intramural NIH research protocol, “Clinical and 
Molecular Investigations Into Ciliopathies”(www.clinicaltrials.gov, trial NCT00068224), 
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approved by the NHGRI Institutional Review Board. The study was advertised by the Joubert 
Syndrome & Related Disorders Foundation. Patients and/or their parents gave written, informed 
consent.  
 
Enrollment required a clinical diagnosis of JS based on the pathognomonic “molar tooth sign” on 
brain MRI. For recruitment, the study was advertised to individuals with JS and their families by 
The Joubert Syndrome and Related Disorders Foundation as a natural history study aiming to 
describe the individual organ system involvement in JS including kidney disease. To minimize 
ascertainment bias, all travel, lodging, and other participation costs, as well as clinical and 
laboratory evaluations, were sponsored by the NIH. A total of 120 patients from 105 families 
who reported to be diagnosed with JS based on brain MRI applied. Brief phone interviews 
answering parents’ questions on risks and benefits of the study evaluations were performed by 
the senior investigator (MGA) on all 120 individuals with JS  from 105 families; no patients 
were excluded at this stage. Fifteen patients could not travel to the NIH Clinical Center in 
Bethesda, Maryland, in some cases due to the severity of neurological symptoms. The remaining 
105 JS patients from 90 families underwent week-long clinical evaluations at the NIH Clinical 
Center. Eight patients from 6 families (including 3 patients with the classical kidney and retina 
findings of Senior-Løken syndrome) were excluded because they did not have the “molar tooth 
sign” on our review of their brain MRI images(17),.The remaining 97 patients were included in 
this study.  
 
All patients were evaluated by the last author (MGA); evaluations included past medical history, 
family history, physical examination, review of past medical records, review of brain magnetic 
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resonance images, high resolution complete abdominal US (all patients), abdominal MRI (13 
patients who were able to cooperate for the study without sedation), complete ophthalmologic 
examination, and comprehensive blood and urine chemistries. Glomerular filtration rate (GFR) 
was calculated using pediatric(18) and adult(19) formulas. Blood samples for DNA were 
collected from all patients and parents, when available.  
 
Kidney disease was defined based on GFR and/or abnormal findings on kidney US including 
increased echogenicity, increased or decreased kidney size, and/or cystic changes. Liver disease 
was defined by elevated liver enzymes and/or increased echogenicity of the liver and/or 
splenomegaly on abdominal US. Retinal degeneration was based on typical findings on retinal 
examination after dilation of pupils. All available brain MR images were qualitatively evaluated 
by a team of five physicians, including two pediatric neuroradiologists, one adult 
neuroradiologist, one pediatric neurologist and one pediatric clinical geneticist (MGA), as a 
group to achieve consensus(17).  
 
Molecular Inversion Probes (MIP), Whole exome and Sanger Sequencing 
The coding exons of 27 genes associated with JS were sequenced by combining a MIP capture 
method and next-generation sequencing as previously described(20). In addition, exome 
sequencing was performed using the HiSeq2000 (Illumina, San Diego, CA)(21) and analyzed as 
previously described(20). For further details, please refer to supplementary methods.  
 
Statistical Methods 




Serum cystatin C was not available in 4 children (Table 1S, patients 26, 31, 82, and 83), due to 
problems in handling of blood specimens. For these patients, GFR was calculated using an 
alternative formula based on height and serum creatinine(22). Abdominal MRI was performed in 
13 of 97 patients who were able to tolerate this study without anesthesia. Therefore, to evaluate 
kidney size ultrasonography based kidney length which was available on all patients was used.   
Results 
Patient Cohort 
Table 1S shows the molecular genetic findings in 97 patients, as well as their major clinical 
features including kidney disease, retinal degeneration, coloboma, liver disease and polydactyly. 
There were 41 females and 56 males. Ages ranged from 0.6 to 36 years (mean 9.0 + 7.6 years) 
(Table1S). Nine families had 2 siblings (Families 6, 7, 8, 18, 24, 29, 36, 65, and 78) and 2 
families had 3 siblings with JS  (Families 16 and 66) evaluated at the NIH. In addition, 4 other 
families represented in this study by a single patient, (Table 1, families 5, 14, 34 and 44) and 
family 66 had another affected deceased child.  
 
The molecular genetic cause was identified in 19 different JS genes in all but 5 families; detailed 
molecular genetic findings of this cohort were reported seperately (20) (Table 1S). Mutations for 
two-thirds of the families resided in 6 genes: TMEM67 (20%), C5orf42 (14%), CC2D2A (11%), 
CEP290 (8%), AHI1 (7%), and KIAA0586 (7%). Each of the remaining 13 genes accounted for a 
small proportion of the families, ranging from 1-6%: MKS1 (6%), INPP5E (4%), NPHP1 (1%), 
TMEM216 (2%), OFD1 (2%), CSPP1 (2%), TMEM231 (1%), KIF7 (1%), B9D1 (1%), 




Retinal degeneration was detected in 20%, coloboma in 30%, polydactyly in 13%, and liver 
involvement in 43% (Table 1S).  
 
Kidney Disease 
Kidney involvement was identified in 29 patients; in the remaining 68 patients, kidney US and 
GFR were normal and there was no hypertension or chronic anemia. (Tables 1 and 2). Four 
patients with kidney disease (Table 2, patients 9, 16, 53 and 73) underwent kidney 
transplantation prior to their NIH evaluation. Of the remaining 25 patients with kidney 
involvement, 24 had abnormalities on kidney US; 13 of these 24 had decreased GFR (Table 2). 
One patient had decreased GFR with normal kidney US.  
Kidney Transplantation 
At the time this paper was written,  13 of the 29 JS patients with kidney involvement had reached 
end stage kidney disease (ESRD) at ages 6-24 years (mean 11.3 + 4.8 years); 7 patients have 
undergone transplantation after their NIH evaluation (Table 2, patients  3, 5, 8, 13, 50, 54, and 
97) and 2 other patients (Table 2, patients 52 and 80) reached ESRD at age 12 years, but have 
not yet been transplanted.  
Kidney-related Findings on Prenatal Ultrasonography 
Prenatal kidney US was abnormal in only 8 (28%) of the 29 patients with kidney disease (Table 
2, patients 5, 8, 13, 50, 53, 56, 72 and 89). In 2 other affected individuals (Table 1S, patients 17 
and 42) prenatal US was normal, but their mothers had other affected pregnancies with enlarged 
diffusely cystic kidneys resulting in fetal demise. In 4 patients (Table 2, patients 5, 8, 13, and 
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89), enlarged, hyperechogenic kidneys with or without discrete cysts and/or oligohydramnios 
were seen at gestational age 19-20 weeks. The mother of patient 5 had another pregnancy with 
similar US findings at 19 weeks. In patient 53, who required kidney transplantation at age 9 
years, prenatal US at 19 weeks showed hyperechogenic kidneys that returned to normal on repeat 
US in the third trimester. Patient 72 had polyhydramnios during the 8th month of pregnancy. In 
patient 3, prenatal US was normal but oligohydramnios was diagnosed at delivery and the 
infant’s kidneys were palpable at birth. In 2 patients (50 and 56), the kidney abnormality was 
unilateral; US at the 20
th
 week of gestation in each infant showed left multi-cystic dysplastic 
kidney (MCDK) and the right kidney was normal.  
Kidney Imaging Findings at the NIH Clinical Center  
The most common abnormality on kidney US was increased echogenicity involving both cortex 
and medulla, resulting in loss of corticomedullary differentiation with or without discrete cysts 
(11 of 24 patients with abnormal US). In 5 of these 11 patients (Table 2, patients 3, 5, 8, 13, and 
89), the kidneys were perinatally enlarged; 1 of these patients still had enlarged kidneys at the 
time of NIH evaluation at age 8 years (Table 2, patient13). In the remaining 4 kidney sized 
normalized or became smaller over time (Figure 2A and B). Patient 60 with left multicystic 
dysplastic kidney, had an enlarged right kidney likely due to compensatory hypertrophy; in the 
remaining 24 patients with kidney disease kidney size was either normal or small (Table 2). In 4 
patients (Table 2, patients 40, 52, 54, and 79) cysts and/or hyperechogenicity were confined to 
medulla (Figure 2D). Asymmetric kidney disease was identified in 4 patients (Table 2, patients 
50, 56, 59 and 60), including 3 with left MCDK (Figure 2E and F). Patient 56’s nuclear scan at 
age 12 months failed to demonstrate any kidney function of the left kidney (Figure 2F) and US at 
19 months showed a normal right kidney, and a small left-sided hypoechoic mass that may have 
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represented an atrophic kidney; his kidney function and voiding cystourethrogram were normal. 
Patient 59’s yearly US examinations between ages 1 to 7 were completely normal. At age 7 
years, the only abnormal finding was a small cortical cyst at upper pole of left kidney; annual US 
imaging between ages 7 and 13 remained otherwise normal. At age 17 years, both kidneys were 
hyperechogenic; left kidney (length at -0.7 SD) had several large cysts in upper pole while right 
kidney was relatively larger (length at +1.9 SD) with a few small cortical cysts.  
 
Kidney Histopathology Findings 
Histopathology of 3 kidney explants (Table 2, patients 8, 9, and 16) showed severe tubular 
atrophy, interstitial fibrosis, chronic inflammation, variable degrees of glomerulosclerosis, 
nephrocalcinosis as well as cysts, mostly accumulated at the CM junction but also scattered 
throughout the cortex and medulla. 
Early-onset Hypertension  
Of the 29 patients with kidney disease, 7 had early-onset hypertension diagnosed shortly after 
birth or within the first years of life, before any measurable decrease in GFR (Table 2). Patient 9 
was screened at age 3 years after his sister’s diagnosis of “polycystic kidneys”; he had 
cardiomyopathy secondary to undiagnosed early-onset severe hypertension which resolved after 
treatment.    
Discussion 
The frequency of kidney disease in our JS cohort was 30%, slightly higher than published 
estimates of 25 to 27 % (9, 10), perhaps a reflection of our comprehensive evaluations performed 
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specifically to detect kidney disease. The percentage of individuals with kidney disease may also 
increase with age; our cohort’s mean age was 9 years.  
Nephronophthisis was present in 31 % of our JS patients with kidney disease, and it resembled 
the kidney disease of  non-syndromic nephronophthisis(23, 24). Clinically, kidney size was 
normal or small, with increased echogenicity and a few cysts at the corticomedullary junction. Of 
the 9 JS patients with nephronophthisis, 2 had Senior-Løken syndrome with retinal degeneration 
due to mutations in CEP290, andINPP5E; the 7 nephronophthisis patients with no retinal disease 
had mutations in CC2D2A, TMEM67 and NPHP1.  
A hybrid ARPKD-nephronophthisis pattern of kidney disease was present in 35% of JS patients 
with kidney disease. One characteristic feature of ARPKD(25) but not nephronophthisis(24), 
present in 7 patients, was early-onset severe hypertension (before any decrease in GFR). Another 
feature of ARPKD, enlarged kidneys, was seen in 5 patients, making the early differentiation of 
JS and ARPKD challenging. In fact, 3 patients (8, 9 and 13) were originally diagnosed as having 
ARPKD and carried this diagnosis until their NIH evaluation under our ARPKD study at ages 6, 
9 and 8 years, (respectively); at that time, their mild oculomotor apraxia and developmental 
delays made us suspect JS. An additional patient, (patient 3) was misdiagnosed as having 
ARPKD in addition to his known diagnosis of JS, which was the cause of his polycystic kidneys. 
Before making a prenatal diagnosis of ARPKD, cerebellar abnormalities and polydactyly should 
be excluded because renal disease in JS is indistinguishable from ARPKD. Only 13% of JS 
patients have polydactyly (Table 1), so a careful evaluation for brain anomalies is essential for 
prenatal differentiation of JS from ARPKD. In addition, if a child diagnosed as having ARPKD 
manifests developmental delay and/or ocular motor apraxia, a brain MRI should be performed 
because patients with JS with mild cerebellar involvement may be misdiagnosed as ARPKD.  
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The combination of coloboma, kidney disease and polydactyly strongly suggests a ciliopathy, 
specifically JS. Molecular studies can also be helpful, since 7 of the 10 patients in the ARPKD-
nephronophthisis group had mutations in TMEM67 and enlarged, ARPKD-like kidneys; indeed, 
mutations in TMEM67 also cause Meckel syndrome, another ciliopathy with cystic kidney 
disease(1).  
Our most surprising finding was unilateral MCKD in 3 JS patients (50, 56 and 60), two of whom 
had a completely normal contralateral kidney and normal GFR at ages 3 (patient 56) and 20 
years (patient 60) (Figure 2E and F, Table 2). Both of these patients had mutations in AHI1. 
While unilateral MCDK occurs as part of many syndromes, asymmetric kidney disease is 
unexpected in ciliopathies(1, 23). We are aware of MCDK reported in JS in the medical 
literature: one Iranian patient with JS and right-sided MCDK(26), and one with either unilateral 
kidney agenesis(7) or unilateral MCDK misdiagnosed as kidney agenesis due to resolution of the 
atrophic kidney(27). Of note, patient 60 in our cohort was part of a previously reported series 
(family K8062)(28). Recently, mutations in HNF1β and TBX18 have been identified in rare 
families with MCDK(29, 30)
,
(31). Our patients, however, had mutations in CEP290 and AHI1 as 
single gene causes of syndromic MCDK associated with JS.  
Modifier genes may influence the occurrence of kidney disease in JS (32). All 11sibling sets 
evaluated at NIH were concordant for kidney disease. However,  in two families, there was 
history of a deceased sibling who was discordant for presence of kidney disease (Table 1S and 
Table 3, families 34, and 66). In family 34 (Table 1S)patient 42 had no significant kidney disease 
at age 3.2 years, despite having an affected brother who passed away perinatally due to cystic 
kidneys. Similarly, in family 66, a 4th child passed away at birth with polycystic kidneys(33), 
while 3 other affected siblings (Table 1S, patients 76, 77 and 78) had normal kidney imaging and 
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function at  ages 15 months and 4 years 9 months (twins). It is possible that these patients may 
develop kidney disease as they get older.  
Prenatal US was abnormal in 28% of JS patients with kidney disease, representing a surprisingly 
low prenatal detection rate of kidney disease in JS. In another multisystem ciliopathy Bardet-
Biedl syndrome(34), Forsythe et al. reported a prenatal detection rate of 64% for kidney disease. 
This discrepancy in prenatal detection rates of kidney disease of patients with JS and Bardet-
Biedl syndromes may be due to the variation in the expertise of the prenatal ultrasonography 
specialists as well as differences in the nature of kidney disease among different ciliopathies.  
We can derive several important conclusions from this study. First, kidney disease affects up to 
one-third of JS patients, and is more common in those with pathogenic variants in CEP290, 
TMEM67 and AHI1 genes; it was not observed in patients with mutations in C5orf42 or 
KIAA0586. Second, the severity and progression of kidney disease appeared comparable across 
JS genotypes, with most patients requiring kidney transplantation in childhood-young adulthood. 
Third, prenatal US does not predict kidney disease well in JS; it was abnormal in only 28% of JS 
patients with kidney disease. Moreover, the prenatal kidney US findings in JS are 
indistinguishable from ARPKD, so fetuses with hyperechogenic kidneys should have careful 
imaging for other abnormalities, especially brain anomalies; in addition, polydactyly, if present 
can be a helpful sign of JS, although its absence does not exclude the condition. Fourth, early-
onset hypertension, before kidney function is decreased, occurred in 24% of JS patients with 
kidney disease, particularly those with enlarged, ARPKD-like, diffusely hyperechogenic 
kidneys. Fifth, in families with multiple children with JS, siblings are largely concordant for 
kidney disease, although exceptions exist. Based on these conclusions, we make several 
recommendations for surveillance. All patients with JS should have blood pressure measurement, 
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complete abdominal US, liver and kidney function tests, and complete blood counts at the time 
of diagnosis and annually thereafter. JS patients with unilateral MCDK should be radiologically 
assessed for other congenital anomalies of the kidney and urinary tract such as vesicoureteral 
reflux or contralateral ureteropelvic junction obstruction(27, 35) (36).   
Limitations 
Although this study represents the largest number of subjects with JS evaluated at a single center, 
the size of the cohort is still relatively small. Gene-phenotype correlations were not possible 
except for the most common genetic causes. Our cohort is likely enriched for JS patients with 
kidney and liver disease, because the comprehensive evaluations performed at the NIH Clinical 
Center may have attracted patients with these manifestations. However, our study also offered 
other investigations including neurocognitive testing, DNA sequencing, sleep studies, and 
echocardiograms, which may have minimized this bias. JS patients with severe disease such as 
those who required mechanical ventilation may be underrepresented, as they could not travel to 
Bethesda, MD. In addition, the overall frequency of kidney disease as well as other extra-
neurological manifestations may have been underestimated by this cross-sectional study because 
these manifestations may develop as the patient gets older.  
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Figure Legends 
Figure 1. Diagnostic brain imaging findings in Joubert Syndrome. A. Axial brain MRI 
obtained at the pontomesencephalic junction showing the molar tooth sign (“MTS”; circle) and 
hypoplastic cerebellar vermis (arrows) compared to normal (C). B. Mid-sagittal brain MRI 
demonstrating hypoplasia and dysplasia of the cerebellar vermis (circle) and enlarged fourth 
ventricle (asterisk) with rostral displacement of the fastigium compared to normal (D). 
 
Figure 2. Imaging findings in JS patients with kidney disease.  
A. Ultrasonographic image of patient 9 at age 4 years showing enlarged and hyperechogenic left 
kidney (outlined by the dots) with loss of corticomedullary differentiation. B. Patient 9’s kidney 
length (bold red line, average of right and left) plotted against age in comparison to normal mean 
(bold gray line) and +2 standard deviation (gray line). C. High resolution ultrasonographic image 
of patient 88’s left kidney displaying cysts in cortex. D. Ultrasonography image of patient 40’s 
left kidney showing medullary hyperechogenicity. E. T2-weighted coronal magnetic resonance 
image of patient 60 showing a left multicystic dysplastic kidney and normal right kidney. F. Tc-
99m nuclear scan (coronal image) of patient 56 at age 12 months showing no function of his left 
MCDK. This patient’s prenatal ultrasonography at 19 weeks of gestation showed a left MCDK 
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and a normal right kidney. On ultrasonography at age 3, his left kidney could not be visualized 
but his right kidney was normal. 
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1 1 361 m 0.9 TMEM67
2 2 545 f 2.2 TMEM67
3 3 97 m 3.9 TMEM67
4 4 548 m 4.5 TMEM67
5 5 216** f 4.9 TMEM67
6 302 m 5.1 TMEM67
7 301 m 9.5 TMEM67
8 271 f 6.7 TMEM67
9 272 m 9.3 TMEM67
10 557 m 6.8 TMEM67
11 559 m 16.7 TMEM67
12 9 459 f 7.8 TMEM67
13 10 238 m 8.2 TMEM67
14 11 255 m 9 TMEM67
15 12 542 f 11.9 TMEM67
16 13 303 f 14.7 TMEM67
17 14 252** f 14.8 TMEM67
18 15 309 m 17.4 TMEM67
19 562 m 22.9 TMEM67
20 561 m 24.9 TMEM67
21 560 m 29.6 TMEM67
22 17 432 f 36.2 TMEM67
23 488 m 0.6 C5orf42
24 487 f 5.3 C5orf42
25 19 355 f 2.1 C5orf42
26 20 458 f 2.2 C5orf42
27 21 523 f 2.3 C5orf42
28 22 471 m 8 C5orf42
29 23 534 f 8.4 C5orf42
30 501 m 10 C5orf42
31 500 f 11.8 C5orf42
32 25 404 m 10.3 C5orf42
33 26 568 f 14.1 C5orf42
34 27 528 m 18.8 C5orf42
35 28 491 m 19 C5orf42
36 482 f 24.5 C5orf42
37 481 m 27.6 C5orf42
38 30 378 f 1.8 CC2D2A
39 31 483 f 2.3 CC2D2A
40 32 575 f 2.3 CC2D2A
41 33 495 m 3.5 CC2D2A
42 34 446** m 3.2 CC2D2A
43 35 185 m 3.6 CC2D2A
44 577 f 13.1 CC2D2A
45 576 f 15.7 CC2D2A
46 37 565 f 15.4 CC2D2A
47 38 364 f 16.3 CC2D2A
48 39 480 m 0.9 CEP290
49 40 552 m 4.3 CEP290
50 41 373 m 4.4 CEP290
51 42 455 m 6.9 CEP290
52 43 412 m 10 CEP290
53 44 213** f 13.2 CEP290
54 45 441 f 23.5 CEP290
55 46 513 m 1.9 AHI1
56 47 517 m 3.3 AHI1
57 48 472 m 5 AHI1
58 49 574 m 5.1 AHI1
59 50 540 f 17.9 AHI1 
60 51 228 f 20.9 AHI1
61 52 443 f 2.2 KIAA0586
62 53 368 m 4 KIAA0586
63 54 494 m 4.4 KIAA0586
64 55 579 m 4.4 KIAA0586
65 56 507 m 4.7 KIAA0586
66 57 531 m 13.6 KIAA0586
67 58 502 m 1.5 MKS1
68 59 397 m 1.7 MKS1
69 60 537 m 2 MKS1
70 61 510 m 8 MKS1
71 62 573 m 14 MKS1
72 63 372 m 3.2 INPP5E
73 64 352 m 14.5 INPP5E
74 7504 f 19 INPP5E
75 7503 f 21 INPP5E
76 520 f 1.2 TMEM231
77 518 f 4.8 TMEM231
78 519 f 4.8 TMEM231
79 67 438 m 3.4 NPHP1
80 68 396 f 9 TMEM216
81 69 408 m 12 TMEM216
82 70 3331 m 4.3 OFD1
83 71 452 m 12.3 OFD1
84 72 466 f 2.3 CSPP1
85 73 387 f 3.5 CSPP1
86 74 409 m 2.1 KIF7
87 75 400 m 4.8 B9D1
88 76 360 m 21.4 RPGRIP1L
89 77 474 f 4.5 TMEM237
90 390 f 1.9 KIAA0753
91 389 m 7 KIAA0753
92 79 449 f 7.9 CELSR2
93 80 393 m 1.7 Unknown 
94 81 578 f 2.3 Unknown 
95 82 570 m 4.7 Unknown 
96 83 419 f 2 Unknown 














































































Gene Prenatal Ultrasonography NIH Kidney US*
Kidney Length (R, 




















































Prenatal US normal. 
Oligohydramnios at delivery, 
kidneys palpable at birth
Diffuse moderate hyperechogenicity, loss of 
CMD, small cysts  in cortex and medulla - 3.6, - 4.3 28£ (12) 
+
NP ARPKD-NPHP
4 4 548 m 4.5 TMEM67 N Loss of CMD - 0.1, +1.5 146 - NP NPHP
5 5 216
f 4.9 TMEM67
18 week, oligohydramnios, 
enlarged diffusely hyperechoic 
cystic kidneys (affected sibling's 
prenatal US showed 
hydrocephalus, large cystic 
kidneys, oligohydramnios)
Several cysts in left kidney, normal echogenicity 





20 week, enlarged diffusely 
hyperechoic kidneys with scattered 
cysts, no oligohydramnios 
Diffuse moderate hyperechogenicity, loss of 
CMD, cysts in cortex and medulla +0.6,  -0.2 27£(8)
+
Extracted R kidney: histopathological findings consistent with 
autosomal recessive polycystic kidney disease and interstitial 
nephritis and glomerulosclerosis ARPKD-NPHP
9 272
m 9.3 TMEM67 N Tx Tx Tx (7)
+
Extracted R kidney: Moderate chronic interstitial nephritis, 
glomerulosclerosis, tubular atrophy, and nephrocalcinosis as well 
as cysts, mostly accumulated at the CM junction but also scattered 
throughout the cortex and medulla ARPKD-NPHP
10 557 m 6.8 TMEM67 N Diffuse mild hyperechogenicity, loss of CMD - 2.5,  -1.9 129 - NP NPHP 
11 559
m 16.7 TMEM67 N
Diffuse moderate hyperechogenicity, loss of 
CMD, medullary cysts -0.5,  -1.3 59 + NP ARPKD-NPHP
13 10 238
m 8.2 TMEM67
19 week, enlarged diffusely 
hyperechoic kidneys with loss of 
CMD, progressive oligohydramnios 
Diffuse moderate hyperechogenicity, loss of 




f 14.7 TMEM67 N Tx Tx Tx (13)
+
Extracted R kidney: (51 gr, 8.5 X 4.4 X 2.8 cm), Extensive 
glomerulosclerosis, tubular atrophy, and interstitial fibrosis with 
severe chronic inflammation without any evidence of dysplasia. A 
few thin walled tubular cysts at CM junction ARPKD-NPHP
17 14 252
f 14.8 TMEM67
N (affected sibling's prenatal US 
showed polycystic kidneys, 
hydrocephalus)
Multiple cysts in cortex and medulla of right 
kidney, normal echogenicity and  CMD - 1.8, - 0.9 83
-
NP
Cystic, unable to 
classify
18 15 309
m 17.4 TMEM67 N
Multiple cysts in cortex and medulla, normal 
echogenicity and  CMD - 0.2, +1.3 106 - NP
Cystic, unable to 
classify
47 39 480
m 0.9 CEP290 N
Multiple cysts in cortex and medulla of right 
kidney, normal echogenicity and CMD - 1.7, -2.8 90 - NP
Cystic, unable to 
classify
48 40 552
m 4.3 CEP290 N
Multiple cysts in cortex and medulla of both 
kidneys, normal echogenicity and  CMD -0.7, -1.4 115 - NP




20 week, left multicystic dysplastic 
kidney; right kidney normal
Atrophic multicystic left kidney without any 
normal parenchyma (5.5cm), several cortical 





51 43 412 m 10 CEP290 N Multiple medullary cysts, normal echogenicity - 0.9, -0.9 35 - NP NPHP
52 44 213 f 13.2 CEP290
19 week, hyperechogenic kidneys, 
(resolved in 3rd trimester) Tx Tx Tx (9) - NA NPHP
53 45 441 f 23.5 CEP290 N Multiple medullary cysts, moderate hyperechogenicity+0.3, -0.9 21£(24) - NP NPHP
55 47 517
m 3.3 AHI1
19 week, left multicystic dysplastic 
kidney; right kidney normal
Left kidney could not be visualized, right kidney 






f 17.9 AHI1 N
Left kidney with several large cysts, right kidney 
normal size with multiple cysts and moderate 
hyperechogenicity 
+1.9, -0.7 (154 ml, 
and 92 ml)¥ 92
-
NP
Cystic, unable to 
classify, 
(asymmetrical)
59 51 228 f 20.9 AHI1 N
Left multicystic dysplastic kidney, Right kidney 
normal (14.9 cm).  
+4.3, atrophic 
MCDK 219 - NP Unilateral MCDK
78 67 438 m 3.4 NPHP1 N Medullary cysts and echogenic foci in medullary pyramids -1.0, +1.3 117 - NP NPHP
79 463
f 15.9 NPHP1 N Tx Tx Tx(11)
-
Extracted L kidney: (175 gr, 9.5 X 6 X 5.3 cm), marked intestitial 
inflammmation with subcapsular as well as deep cortical 
glomerulosclerosis, interstitial fibrosis and atrophy with medullary 
cysts    NPHP
80 462 m 18.1 NPHP1 N Tx Tx Tx (13) - nephronophthisis/medullary cystic disease NPHP
39 32 575 f 2.3 CC2D2A N Medullary "nephrocalcinosis" -1.8, -0.5 119 - NP NPHP
42 35 185 m 3.6 CC2D2A N Loss of CMD -3.4, -2.0 66 - NP NPHP
71 63 372
m 3.2 INPP5E 8 months, oligohydramnios 
Multiple medullary cysts, loss of CMD, 
moderate hyperechogenicity +3.9, +3.7 137 - NP ARPKD-NPHP
72 64 352 m 14.5 INPP5E N Tx Tx Tx(6) - NP NPHP
81 69 396
f 9 TMEM216 N N +0.5, -1.64 52
-
NA
Cystic, unable to 
classify, ( bladder 
dysfunction)
89 77 290 f 8 CEP164 N Tx Tx Tx(7)π -
Biopsy at age 5 years: Chronic sclerosing tubulointerstitial 
nephropathy; there were no cysts NPHP-like
90 78 360 m 21.4 RPGRIP1L N Diffuse moderate hyperechogenicity, loss of CMD, cysts in medulla and cortex +2.0, +1.3 33 - NP ARPKD-NPHP
97 79 474
f 4.5 TMEM237
20 week, enlarged (3 times normal 
size) kidneys with markedly 
increased echogenicity
Diffuse moderate hyperechogenicity, loss of 
CMD, echogenic foci and cysts in medulla and 




m 9.1 Unknown N
Moderate hyperechogenicity especially in the 
cortex, single cortical cyst in right kidney -0.5. -0.5 34£(15) - NP
Cystic, unable to 
classify
Patients are grouped by gene and within each gene patients are sorted from the youngest to oldest. US: renal ultrasonography;  SD: standard deviation; GFR: glomerular filtration rate; CMD:corticomedullary differentiation; NP: not performed; NPHP: 
nephronophthisis; ARPKD: autosomal recessive polycystic kidney disease; *Kidney ultrasonography findings are bilateral unless otherwise specified  ¥Hypertension diagnosed before any decrease in GFR. Tx( ): Transplanted(age at transplantation in years);  £ 




Table 2. Characteristics of Kidney Disease in 32 Joubert Syndrome patients with Kidney involvement
